Recent incidence trend of elderly patients with glioblastoma in the United States, 2000–2017

Abstract

Background The incidence of glioblastoma increases significantly with age. With the growing and aging population, there is a lack of comprehensive analysis of recent glioblastoma incidence trend in the United States. This study aims to provide in-depth description of the patterns of incidence trends and to examine the age-period-cohort effects to the trends of glioblastoma specific to elderly patients. Methods The incidence rates were age-adjusted and reported per 100,000 population. We calculated the annual percent change (APC) in incidence using the Joinpoint Regression Program and conducted an age-period-cohort analysis of elderly glioblastoma reported between 2000 and 2017 to the Surveillance Epidemiology and End Results (SEER) 18 registry database. Results The overall incidence rate of elderly patients with glioblastoma was 13.16 per 100,000 (95% CI, 12.99–13.32) from 2000 to 2017. Non-Hispanic whites (20,406, 83.6%) made up the majority. The incidence rate of male was about 1.62 times that of female. The trend of incidence remained stable and there was a non-significant increasing tendency for all elderly patients (APC 0.3, 95% CI, − 0.1 to 0.7, p = 0.111). There was a significantly increasing incidence trend for non-Hispanic white (APC 0.6, 95% CI, 0.2 to 1.1, p = 0.013), supratentorial location (APC 0.7, 95% CI, 0.2 to 1.3, p = 0.016), tumor size < 4 cm (APC 2.5, 95% CI, 1.4 to 3.6, p < 0.001), and a significantly decreasing trend for overlapping/NOS location (APC -0.9, 95% CI, − 1.6 to − 0.2, p = 0.012), and unknown tumor size (APC -4.9, 95% CI, − 6.6 to − 3.3, p < 0.001). The age-period-cohort analysis showed the effect of age on incidence trends (p< 0.001, Wald test), while did not indicate the period and cohort effects of the incidence trends of glioblastoma (p = 0.063 and p =0.536, respectively, Wald test). Conclusion The overall incidence of glioblastoma in the elderly population remained stable between 2000 and 2017. Period and cohort effects were not evident in the trend of glioblastoma incidence. Future population-based studies exploring the difference in the trend of glioblastoma incidence by specific molecular subgroups are warranted to further our understanding of the etiology of glioblastoma.

Dynamic Intercell Communication between Glioblastoma and Microenvironment through Extracellular Vesicles

“…A study in the United States showed that the average incidence rises with age. If we consider the whole population of the United States, the incidence stands at around 3.2 per 100,000 people [4,13], which is in accord with the worldwide average incidence that ranges from 0.59 to 5 per 100,000 people [14]. If we age adjust occurrences of glioblastoma, we see that the incidence rate rises to 15.47 per 100,000 people in age group ranging from 75 to 79 years old [13].…”

“…If we consider the whole population of the United States, the incidence stands at around 3.2 per 100,000 people [4,13], which is in accord with the worldwide average incidence that ranges from 0.59 to 5 per 100,000 people [14]. If we age adjust occurrences of glioblastoma, we see that the incidence rate rises to 15.47 per 100,000 people in age group ranging from 75 to 79 years old [13]. The same thing was pointed out when Walker et al looked at the Canadian population between the years 2009 and 2013.…”

CircNUP98 Suppresses the Maturation of miR-519a-3p in Glioblastoma

“…However, even with timely and effective treatment, only 25 and 5% of patients can survive for more than 1 and 5 years, respectively, and the average survival time is only 12–18 months ( 6 , 7 ). Even worse, with the growth of aging population, incidence of GBM is increasing, leading to a serious threat to public health ( 8 ). Therefore, improving of GBM treatment is of great importance.…”

Geriatric Neuro-Oncology in the Middle East: A Sultanate of Oman Experience

“…The incidence of GBM increases tremendously with age peaking between ages of 65 to 84 [7]. The overall incidence of GBM in the elderly is 13.16 per 100,000 persons [11]. Patients with GBM often have a poor prognosis with a median survival rate of 2 years despite therapeutic advances [11].…”

“…The overall incidence of GBM in the elderly is 13.16 per 100,000 persons [11]. Patients with GBM often have a poor prognosis with a median survival rate of 2 years despite therapeutic advances [11]. Also, anaplastic astrocytoma (AA) is a diffusely infiltrating malignant, astrocytic primary brain tumor [12].…”